Welcome to our dedicated page for Electromed SEC filings (Ticker: ELMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Electromed, Inc. filings document formal disclosures for a Minnesota operating company focused on airway clearance technologies. Recent Form 8-K reports furnish quarterly financial results, Regulation FD investor presentations, share repurchase authorization disclosures, and material financing information tied to a senior secured revolving credit facility.
The company's proxy and shareholder-vote filings cover director elections, auditor ratification, advisory executive compensation votes, board and governance matters, and equity-compensation disclosures. These records also describe capital-allocation actions, debt covenants, financial condition updates, and exhibit materials associated with press releases, credit agreements, and investor presentations.
Electromed, Inc. reported that one of its directors acquired 3,000 shares of common stock as a restricted stock award on December 1, 2025 at a stated price of $0 per share. After this award, the director beneficially owns 15,000 shares of Electromed common stock in direct ownership form. The restricted stock is scheduled to vest on June 1, 2026, unless vesting is accelerated or the award is terminated under its terms, meaning the director must remain eligible through that date to receive the shares without restrictions.
Electromed, Inc. reported an insider stock award for one of its directors. On 12/01/2025, the director acquired 3,000 shares of common stock, described as restricted stock, at a price of $0 per share. After this grant, the director beneficially owns 35,622 shares of Electromed common stock.
The restricted shares are scheduled to vest on June 1, 2026, unless they are accelerated or terminated under their terms. This filing is a routine disclosure of insider equity compensation and does not involve a public offering or sale of shares into the market.
Electromed, Inc. director and 10% owner received additional equity in the company. On December 1, 2025, the reporting person acquired 3,000 shares of Electromed common stock as restricted stock at a stated price of $0. After this grant, the reporting person holds 12,000 shares directly.
The filing also reports 270,367 shares held indirectly through Summers Value Fund LP. An explanation notes that this balance includes 100 additional shares identified through a routine reconciliation of ownership records. The 3,000 restricted shares are scheduled to vest on June 1, 2026, unless vesting is accelerated or the award is terminated under its terms.
Electromed, Inc. (ELMD) reported the results of its annual shareholder meeting held on November 14, 2025. Shareholders elected all nominated directors to the Board, with each nominee receiving substantially more votes "for" than "withheld." Other management proposals also received strong support, including the advisory vote approving executive compensation. Shareholders additionally voted on how often they want an advisory vote on executive pay, and the Board determined, based on these results, to continue including this vote in the proxy materials on an annual basis. These outcomes keep the company’s governance structure and executive pay practices largely unchanged.
Electromed, Inc. (ELMD) reported stronger Q1 FY2026 results. Net revenues rose 15.1% to $16,887,000, led by homecare ($14,889,000), hospital ($1,047,000), and homecare distributors ($829,000). Gross profit was $13,197,000 at 78.1% of revenue. Operating income increased to $2,670,000 and net income grew 44.9% to $2,136,000, with diluted EPS of $0.25.
SG&A was $10,286,000, reflecting investments in sales, travel, and marketing; R&D was $241,000. Cash and cash equivalents were $14,113,000, and total shareholders’ equity reached $44,745,000. Operating cash flow was $169,000 after seasonal compensation payouts and inventory build; capital expenditures were $252,000. The company has a $2,500,000 revolving credit facility with no borrowings outstanding.
Capital returns: A stock repurchase authorization of up to $10,000,000 was approved on September 9, 2025; during the quarter, 40,848 shares were repurchased for $1,003,000 at an average of $24.57. Shares outstanding were 8,340,538 as of November 5, 2025. Management cites a working capital position of approximately $35,800,000 and states liquidity is sufficient for the next twelve months.
Electromed, Inc. (ELMD) furnished an 8-K announcing it issued a press release with financial results for the first quarter ended September 30, 2025, and updated its investor presentation. The press release is furnished as Exhibit 99.1 and the presentation as Exhibit 99.2.
The company noted that the information, including Exhibits 99.1 and 99.2, is being furnished and not filed under the Exchange Act, and will not be incorporated by reference into a Securities Act registration statement except as specifically referenced.
Electromed, Inc. is asking shareholders to vote at a fully virtual annual meeting on November 14, 2025. Holders of its 8,376,147 outstanding common shares as of September 17, 2025 can attend and vote online via webcast.
Shareholders will elect eight directors, ratify RSM US LLP as auditor for the year ending June 30, 2026, approve on an advisory basis executive compensation, and choose how often future say‑on‑pay votes are held, with the Board recommending annual votes. The Board recommends voting for all director nominees and for Proposals 2 and 3.
The proxy details compensation for CEO James Cunniff and CFO Bradley Nagel. In fiscal 2025, Cunniff’s total reported pay was $1,486,329, including a $519,231 salary and a $405,600 bonus, while Nagel received $756,674, including a $323,281 salary and a $202,800 bonus after a 156% payout under the 2025 bonus plan. Equity grants include time‑vested restricted stock and options. The filing also shows net income rising to $7,537,000 in 2025 and an increase in total shareholder return since 2023, and outlines board independence, committee structure, equity plans, and related‑party transaction oversight.
Andrew Summers, a director of Electromed, Inc. (ELMD), reported multiple open-market sales of company common stock on September 10 and 11, 2025. The Form 4 shows sales of 39,378, 16,203, 6,576, 404 and 3,153 shares at weighted average prices between $23.6791 and $26.6246, with sale price ranges disclosed for each lot. Some holdings are reported as indirectly owned by investment vehicles (SVP Deal Fund I LP and Summers Value Fund LP), and the filing disclaims direct beneficial ownership except to the extent of pecuniary interest. One reported sale of 3,153 shares on 09/11/2025 reduced the reporting person’s indirect holding in a specified vehicle to 0 shares according to the form. The filing is signed by an attorney-in-fact on behalf of the reporting person.
Electromed, Inc. (ELMD) Form 144 reports a proposed sale of 65,714 shares of common stock via BTIG, LLC on the NYSE American with an aggregate market value of $1,554,136.10. The shares were acquired in the open market on 06/01/2021 and paid for in cash. The filing lists 8,349,176 shares outstanding for the class and shows no securities sold in the past three months. The proposed sale is scheduled for 09/10/2025. The filer affirms there is no undisclosed material adverse information.
Electromed, Inc. announced that its board of directors has approved a new share repurchase authorization. The company may buy back up to $10.0 million of its outstanding common stock over time through open market purchases and privately negotiated transactions. The actual amount and timing of any repurchases will depend on market conditions and other corporate considerations. Details were provided in a press release attached as an exhibit.